Summarized by Masters of Longevity from Neuroscience News.
A Science review found mixed evidence that GLP‑1 drugs may protect cognition in metabolic patients.
Key Takeaways
- Rodent studies showed GLP‑1 drugs reduce inflammation and support synapses.
- Semaglutide altered biomarkers but did not slow early Alzheimer’s decline.
- Early treatment in metabolic patients may protect processing speed.